| Dr Alicia Kittle, AUD | |
|
1210 S Cedar Crest Blvd Ste 1100, Allentown, PA 18103-6241 | |
| (610) 402-7999 | |
| Not Available |
| Full Name | Dr Alicia Kittle |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 1210 S Cedar Crest Blvd Ste 1100, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861876872 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AT006428 (Pennsylvania) | Primary |
| Provider Name | Lehigh Valley Physician Group |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
The government will allow consumers who experience life changes, such as a marriage or the birth of a child, to update their plan choices, the administration said. It is also looking at requiring insurers to accept third-party payments, such as those made under the Ryan White CARE Act, to help people with HIV/AIDS pay for expensive drugs. Meanwhile, The Washington Post examines the history of Accenture, the contractor hired to fix healthcare.gov, and finds troubled projects and allegations of ethical lapses.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles.
The technology that allows scientists to profile the entire genome of individual tumors offers new hope for discovering ways to select the best treatment for each patient's particular type of cancer. However, these profiles produce huge amounts of data, and the volume alone creates unique analytical problems.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alicia Kittle, AUD Po Box 1830, Allentown, PA 18105-1830 Ph: (484) 862-3194 | Dr Alicia Kittle, AUD 1210 S Cedar Crest Blvd Ste 1100, Allentown, PA 18103-6241 Ph: (610) 402-7999 |
News Archive
The government will allow consumers who experience life changes, such as a marriage or the birth of a child, to update their plan choices, the administration said. It is also looking at requiring insurers to accept third-party payments, such as those made under the Ryan White CARE Act, to help people with HIV/AIDS pay for expensive drugs. Meanwhile, The Washington Post examines the history of Accenture, the contractor hired to fix healthcare.gov, and finds troubled projects and allegations of ethical lapses.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles.
The technology that allows scientists to profile the entire genome of individual tumors offers new hope for discovering ways to select the best treatment for each patient's particular type of cancer. However, these profiles produce huge amounts of data, and the volume alone creates unique analytical problems.
› Verified 4 days ago
Lisa Ann Parliman, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1575 Pond Rd Ste 203, Allentown, PA 18104 Phone: 610-366-1366 Fax: 610-366-7412 | |
Lehigh Valley Better Balance Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2015 W Hamilton St, Allentown, PA 18104 Phone: 484-619-3238 | |
Dr. Peter David Kleckner, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3131 College Heights Blvd, Allentown, PA 18104 Phone: 610-435-8299 | |
Elezabeth Labib-zuniga, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 1575 Pond Rd Ste 203, Allentown, PA 18104 Phone: 610-366-1366 | |
Emily Golosky, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3050 Hamilton Blvd Ste 210, Allentown, PA 18103 Phone: 610-395-8224 | |
Elise Lerario, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1210 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-7999 Fax: 610-402-7995 | |
Kleckner Audiology Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3131 College Heights Blvd Ste 2600, Allentown, PA 18104 Phone: 610-435-8299 Fax: 610-435-1940 |